title: [Comparison of the efficacy and tolerability of sustained-release verapamil and captopril in mild to moderate essential arterial hypertension].
abstract: A randomised, double-blind, double-placebo trial compared the efficacy and safety/acceptability of sustained release verapamil and of captopril in two parallel groups of patients with mild to moderate hypertension. After a 2 week placebo period, 45 patients were randomised into 2 groups, the 1st group (n = 22) given sustained release verapamil (240 mg/24 h) as a single morning dose and the second (n = 23) captopril 25 (50 mg/24 h) as two daily divided doses. Treatment was given for 75 days, with the possibility of a combination of sustained release verapamil + captopril from day 45 onwards if diastolic blood pressure remained at 95 mmHg or more. After 45 days of treatment, the reduction in supine diastolic blood pressure did not differ significantly in the 2 groups (-10.4 mmHg in the sustained release verapamil group and -9.7 mmHg in the captopril), with 68.2 per cent responders to sustained release verapamil and 52.2 per cent in the captopril group. After 75 days of treatment, once again there was no significant difference in efficacy between the two groups: -14 mmHg for diastolic pressure and 80 per cent responders in patients treated with sustained release verapamil, -11.3 mmHg and 62.5 per cent responders in the captopril group. The percentage of responders was 58.3 per cent in the group treated with the combination of sustained release verapamil + captopril from day 45 onwards. The number of patients showing evidence of clinical or electrocardiographic adverse reactions was not significantly different: 20.7 per cent in the sustained release verapamil group and 34.8 per cent in the captopril group.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service Développement Clinique, Laboratoires Biosédra, Malakoff.
authors.forename: M
authors.initials: M
authors.lastname: Maarek-Charbit
authors.forename: D
authors.initials: D
authors.lastname: Stephan
authors.forename: M
authors.initials: M
authors.lastname: Welsch
authors.forename: C
authors.initials: C
authors.lastname: Galey-Arcangioli
authors.forename: J L
authors.initials: JL
authors.lastname: Imbs
mesh_terms: D000328:Adult; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D003692:Delayed-Action Preparations; D002216:Captopril; D014700:Verapamil
vernacular_title: Comparaison de l'efficacité et de la tolérance du vérapamil à libération prolongée et du captopril dans l'hypertension artérielle essentielle, légère à modérée.